Lianhua Qingwen prescription for Coronavirus disease 2019 (COVID-19) treatment: Advances and prospects
Data
2020Autor
Li, Liu-Cheng
Zhang, Zhi-Hui
Zhou, Wen-Cheng
Chen, Jie
Jin, Hua-Qian
Fang, Hong-Mei
Chen, Qin
in, Ye-Cheng J
Qu, Jiao
Kan, Lian-Di
Metadata
Mostrar registro completo
Documentos PDF
Resumo
Background: An outbreak of Coronavirus Disease 2019 (COVID-19) which was infected by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), is still spreading and has led to unprecedented health emergency
over the world. Though no specific drug has been developed so far, emerging agents have been confirmed
effective or potentially beneficial to restrain it. Lianhua Qingwen (LHQW) is a commonly used Chinese medical
preparation to treat viral influenza, including in the fight against SARS in 2002–2003 in China. Recent data also
showed that LHQW played a vigorous role in COVID-19 treatment.
Purpose: This review will elucidate the pre-clinical and clinical evidence of LHQW in lung protection and antiviral
activities, and provide timely data delivery for the exploration of effective treatment strategies in the therapy of
COVID-19.
Study design and method: The research data were obtained from the academic databases (up to August 8, 2020)
including Pubmed, CNKI and Web of Science, on ethnobotany and ethno medicines. The search keywords for
screening the literature information were “virus”, “COVID-19”, or “SARS-CoV-2”, and “Lianhua Qingwen”. The
documents were filtered and summarized for final evaluation.
Results: The collected evidence demonstrated that LHQW exhibited benefits against COVID-19. Impressively,
LHQW in conjunction with conventional treatment could significantly improve COVID-19 patients as a synergetic
strategy. The mechanisms were mainly involved the antiviral activity, and regulation of inflammation response
as well as immune function.
Conclusion: Although the data were far from adequate, the latest advances had shown the benefits of LHQW in
COVID-19, especially in combination with other antiviral drugs. This review provides comprehensive evidence of
LHQW as a complementary strategy for treating COVID-19. Nevertheless, imperious researches should be conducted to clarify the unconfirmed effects, regulatory mechanisms and adverse reactions of LHQW in treating
COVID-19 by means of well designed randomized controlled trials.
Palabras clave
Coronavirus; SARS-CoV-2; Lianhua Qingwen; Antiviral activity; Complementary strategyLink para o recurso
https://doi.org/10.1016/j.biopha.2020.110641Collections
Estadísticas Google Analytics
Comments
Respuesta Comentario Repositorio Expeditio
Gracias por tomarse el tiempo para darnos su opinión.